Reata Pharma up as rare disease drug becomes commercially available

Reata Pharmaceuticals

28/06/2023 12:26

** Shares of Reata Pharmaceuticals  RETA.O  rise ~10% to
$101.33 premarket
    ** Co says its rare genetic disorder drug, Skyclarys, is now
commercially available for treating Friedreich's ataxia (FA) in
adults and adolescents aged 16 years and older
    ** RETA says U.S. FDA has approved its application to update
the "drug substance specification" for Skyclarys
    ** The drug was approved by the FDA in February this year
for treating FA, a neuromuscular disorder that causes muscle
weakness and loss of coordination
    ** As of last close, RETA shares up ~143% this year 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))